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Context: Pulmonary carcinoids (PC) belong to neuroendocrine tumors that often overexpress 
somatostatin receptors (SSTR). This overexpression provides a molecular basis for tumor 
imaging and treatment with somatostatin analogs.  
Objective: To evaluate SSTR1–5 distribution in a large set of PC tumors and to investigate 
whether the expression is associated with clinicopathological and outcome data.  
Design, setting and patients: This retrospective study was conducted at Helsinki University 
Hospital and University of Helsinki. It included 178 PC tumors coupled with patients’ 
clinical data retrieved through Finnish biobanks. After histological re-classification, tissue 
specimens were processed into next-generation tissue microarray format and stained 
immunohistochemically with novel monoclonal SSTR1-5 antibodies.  
Main outcome measure: SSTR1-5 expression in PC tumors. 
Results: Expression of SSTR1–5 was detected in 52%, 75%, 56%, 16%, and 32% of the 
tumors, respectively. Membrane-bound staining was observed for all receptors. SSTR2 
negativity and SSTR4 positivity was associated with lymph node involvement at the time of 
surgery (P=0.014 and P=0.017, respectively) and with distant metastasis (P=0.027 and 
P=0.015, respectively). SSTR3 and SSTR4 expression was associated with increased risk of 
shorter survival (P=0.046, HR 4.703, 95% CI 1.027-21.533 and P=0.013, HR 6.64, 95% CI 
1.48-29.64, respectively) while expression of SSTR1 and SSTR2 was associated with 
improved outcome (P=0.021, HR 0.167, 95% CI 0.037–0.765 and P=0.022, HR 0.08, 95% CI 
0.01-0.70, respectively).  
Conclusion: SSTR1–5 expression is observed in pulmonary carcinoids. As SSTR expression 
is associated with the tumor’s metastatic potential and patient outcome, these receptors may 
offer the possibility for individualized prognosis estimation. 
Pulmonary carcinoid tumors express all five somatostatin receptors (SSTR). Immunohistochemical 
expression of SSTR3 or SSTR4 or lack of expression of SSTR1 or 2 are potential prognostic factors. 
Introduction 
Pulmonary carcinoids (PC) belong to pulmonary neuroendocrine neoplasms that are divided 
into four entities based on their differentiation, grade and worsening prognosis (1). Typical 
and atypical carcinoids (TCs and ACs), defined jointly as pulmonary carcinoids, are well-
differentiated, low- and intermediate-grade tumors, respectively. Large cell neuroendocrine 
carcinoma (LCNEC) and small cell lung cancer (SCLC) are poorly differentiated high-grade 
tumors. PCs differ from LCNEC and SCLC by presenting less genetic alterations and a more 
favourable prognosis (2). This study included only PC tumors. 
Pulmonary carcinoids are rare neoplasms with an incidence of approximately 1% of all 
lung cancers (3, 4). Differentiation into TC and AC is based on the presence of mitoses and 
necrosis (1). PCs have in general a good prognosis, especially when resected, but 5–30% of 
patients still die of metastatic disease (5, 6). 
Somatostatin (SST) is a polypeptide hormone that is widely distributed throughout the 
central nervous system as well as different peripheral tissues and organs. It is regarded as a 
secretory pan-inhibitor but is also involved in antiproliferative actions (7). The physiological 
actions of SST are mediated via a family of specific membrane-bound receptors, the 
somatostatin receptors (SSTR) (8). These G protein coupled receptors consist of five 
subtypes: SSTR1–5, where SSTR2 exists in two variants (SSTR2A and SSTR2B). 
Neuroendocrine tumors (NETs) overexpress SSTRs, which provides a molecular basis for 
tumor imaging and therapeutic interventions with somatostatin analogs (SSAs) (9, 10). First-
generation SSAs, octreotide and lanreotide, are approved for carcinoid symptom control as 
well as for antitumor activity in metastatic NETs (11). They bind preferably to SSTR2 and 
with lower affinity to SSTR5 and SSTR3. To expand the clinical application of SSAs, 
multireceptor targeting analogs have been developed, namely pasireotide, somatoprim, and 
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KE108 (12). Of these, SSTR5, 2, and 3 targeting pasireotide is currently under phase I and II 
trials to evaluate the efficacy and safety in NET patients. Somatoprim has been studied in 
phase I and II trials in acromegalic patients while KE108 is not yet under clinical trials (13). 
However, SSTR based imaging and therapy options are only available for patients with an 
SSTR positive tumor. Thus, knowing the expression pattern of different SSTRs of the tumor 
allows better tailoring of SSA based treatment. 
There are a few reports on immunohistochemical analysis of SSTR expression in PCs 
(14-17) but to our knowledge, less studies have evaluated the SSTR expression in regard to 
patient outcome. The objectives of this study were: 1) to further verify the use of SSTR-
mediated diagnostic and therapeutic options by evaluating immunohistochemically the SSTR 
expression in a large set of PCs, 2) to evaluate whether SSTR expression can be used to 
distinguish between TCs and ACs, and 3) to correlate the expression of SSTRs with 
histological features, tumor spread, and patient outcome. 
Materials and Methods 
Patients 
A total of 178 formalin-fixed paraffin-embedded (FFPE) primary tumor tissue samples 
coupled with metastatic samples were obtained from three regional Finnish referral centers 
(Helsinki University Hospital, Turku University Hospital, and Kuopio University Hospital) 
through local biobanks (Helsinki Biobank, Auria Biobank, and Biobank of Eastern Finland, 
respectively). One hundred and thirty-two primary tumor samples with 14 metastatic samples 
were retrieved from the Helsinki Biobank, Helsinki, Finland, 32 primary tumor samples from 
the Auria Biobank, Turku, Finland, and 14 primary tumor samples from the Biobank of 
Eastern Finland, Kuopio, Finland. To achieve at least a 5-year follow-up time for most of the 
patients, only tumors resected between January 1990 and August 2013 were included. 
Following the World Health Organization’s (WHO’s) 2015 classification of pulmonary 
neuroendocrine tumors (1), each sample was re-evaluated on diagnostic whole slides by a 
pathologist with special expertise in pulmonary pathology. One hundred and thirty-eight 
(78%) patients were diagnosed with TC and 40 (22%) with AC. Neuroendocrine 
differentiation was confirmed by routine immunohistochemical staining for chromogranin A, 
synaptophysin, and pan-cytokeratin. 
Surgery was the first-line treatment for most of the patients while two of them received 
also neoadjuvant treatment. First one was given pre-operative radiotherapy because of 
metastatic disease at the time of diagnosis. Second one received both radiotherapy and 
chemotherapy because of SCLC diagnosis based on fine needle biopsy. Table 1 describes the 
clinicopathological features and surgical procedures of the patients. None of the patients 
received adjuvant therapy. 
Thirteen patients had histologically verified lymph node metastasis at the time of 
diagnosis, and two of them had also a metastatic lesion in the liver or pleura. In addition, 
during the follow-up, 17 patients developed distant metastasis in bones, the liver, or the brain. 
Treatment of metastatic disease is described in the Table 2.  
The Finnish Biobank Act (18) allows the transfer of clinical samples into a biobank 
following a specific notification procedure and subsequent opt-out mechanism (19). A 
project-specific consent from the patients is not needed since the Biobank Act provides a 
lawful basis for research use. Thus, this study was approved by the scientific and ethical 
committees of all biobanks (Helsinki Biobank: HUS/359/2017, Auria Biobank: AB16-4487, 
and Biobank of Eastern Finland: 323/2017) as well as by the Surgical Ethics Committee of 
the Helsinki University Hospital (226/E6/2006, April 17, 2013). 
Next-generation tissue microarray construction 
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Next-generation tissue microarray (ngTMA) construction relays on careful TMA planning 
and design, digital pathology and automated tissue microarraying (20). Briefly, after 
histological review, a fresh hematoxylin-eosin (H&E) stained slide was prepared from each 
FFPE tissue sample and digitized with a Pannoramic slide scanner (3D HISTECH, Budapest, 
Hungary) or NanoZoomer-XR (Hamamatsu Photonics, Hamamatsu City, Japan). Digitized 
slides were uploaded onto CaseViewer (3D HISTECH) or NDP.view2 (Hamamatsu 
Photonics) software where areas for ngTMAs were marked with TMA annotation tool. To 
take into account tumor heterogeneity, two representative 1 mm cores from the middle of the 
tumor as well as two cores from the tumor border were selected. For metastatic samples, two 
representative 1 mm cores were marked. TMAs were constructed in the biobanks using a 
TMA Grand Master (3D HISTECH) or Galileo TMA CK4500 (Isenet, Milan, Italy) 
microarrayer. 
Immunohistochemistry 
Immunohistochemical stainings were performed either in the diagnostic laboratory (SSTR2) 
or research laboratory (SSTR1 and SSTR3-5) after careful optimization of each staining 
protocol. Fresh 3.5 µm thick tissue sections were cut with a microtome onto positively 
charged slides. After deparaffinization, a heat-induced antigen retrieval was performed, and 
the sections were incubated with primary antibodies (Table 3). Antibody binding was 
visualized using a polymer-based OptiView Universal DAB Detection Kit (Ventana Medical 
Systems, Inc., Tucson, AZ, USA) or EnVision Detection System (Dako, Agilent Pathology 
Solutions, Santa Clara, CA, USA). Automated (BenchMark ULTRA, Ventana) or semi-
automated (AutoStainer, Lab Vision Corp., Fremont, CA, USA) staining instruments were 
used. All slides were counterstained with Mayer’s hematoxylin (Dako). Appropriate positive 
controls (pancreas, small intestine) and negative control (no primary antibody) were used for 
each antibody. 
Scoring of the staining results 
All immunohistochemical stainings were digitized with a Pannoramic slide scanner (3D 
HISTECH). By using the CaseViewer software (3D HISTECH) for viewing the slides, H.L 
and T.V. performed the scoring manually. No image analysis softwares were used. As shown 
by many previous studies, SSTR2 presents almost exclusively membranous staining while 
other SSTRs are also expressed in the cytoplasm (14-16). Thus, immunoreactivity of the 
strongest labeled TMA spot was classified based on solely membranous staining (SSTR2) or 
both cytoplasmic and membranous staining (SSTR1, SSTR3, SSTR4, and SSTR5) (Fig. 1a-
e). A similar scoring system to that introduced by Elston et al. (21) and Körner et al. (22), 
was used for membranous staining. Cases were scored as negative (0) if no staining was 
observed, and weak (1) if partial membranous positivity in <10% of the tumor cells was 
detected. A moderate (2) score was given if partial membranous positivity was observed in 
≥10% of the tumor cells. A strong (3) score was assessed if circumferential membranous 
positivity was observed on the tumor cells, and an intense (4) score if >95% of the tumor 
cells had a strong, circumferential staining pattern.  
As SSTR1, SSTR3, SSTR4, and SSTR5 showed also cytoplasmic reactivity, the 
following scoring system was used: 0, negative; 1, weak intensity; 2, moderate intensity; and 
3, strong intensity. Tumors were considered positive if a moderate or strong cytoplasmic 
staining pattern was found in ≥5% of the tumor cells and/or when a membrane pattern was 
observed with a score of 2 or higher. 
Statistical analysis 
Differences in the continuous variables between the groups were calculated with the Mann-
Whitney U test while the Fisher’s exact test was used for dichotomous variables. The 
Spearman’s rank correlation coefficient was used for the pairwise correlation analyses of 
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expression between different SSTRs. The Kaplan–Meier method with a log-rank test was 
exploited to estimate cumulative survival probabilities as well as to graphically display the 
disease-specific survival (DSS) curves. Differences in hazard rates by SSTR status were 
tested with the univariate Cox survival regression model. Survival was calculated from the 
date of the surgery to the last date of follow-up or death. Duration of the clinical response and 
benefit from the first-line somatostatin analog or peptide receptor radionuclide therapy was 
measured from the date of the start of the treatment to the date of the start of chemotherapy or 
the date of death due to any cause, whichever came first. The level of statistical significance 
was set to 0.05. Two-tailed tests were used. Calculations were performed by statistical expert 
using IBM SPSS Statistics for Windows, Version 24.0 (IBM Corp., Armonk, NY, USA) and 
MedCalc Software, Version 18.5 (Ostend, Belgium). 
Results 
Somatostatin receptor status 
SSTR2 was expressed most frequently, followed by SSTR3, SSTR1, SSTR5, and SSTR4 in 
the whole series of tumors. Membrane-bound staining was observed for all receptors. For 
SSTR2, it was a dominant staining pattern while other receptors showed also cytoplasmic 
staining. 
SSTR1 
Overall, 62% of the tumors expressed SSTR1 on the cell membrane (Fig. 2a), while 52% 
(n=88) of the tumors were considered positive based on the criteria presented in the methods 
section (Fig. 2b). No significant difference in the SSTR1 staining pattern was seen between 
TCs and ACs. Ten out of 12 (83%) primary tumor sample / metastatic sample pairs showed a 
similar staining pattern: in two cases the primary tumor did not express SSTR1 but the 
metastatic sample did (Table 4). 
SSTR2 
Altogether, 86% (n=153) of the tumors demonstrated SSTR2 membranous reactivity (Fig. 
2a). TCs showed more often SSTR2 expression compared with ACs (P=0.007). We further 
categorized the SSTR2 expression as either negative or positive by grouping together the 
membrane scores 0–1 and 2–4, respectively. Within these two categories, 75% of the tumors 
were positive (Fig. 2b). All metastatic samples showed a staining pattern similar to that of the 
primary tumors (Table 4). 
SSTR3 
SSTR3 staining was positive in 56% (n=98) of the tumors, cytoplasmic staining being shown 
in each tumor (Fig. 2b). In addition, 28% (n=49) of the tumors demonstrated also 
membranous reactivity (Fig 2a). No significant difference in SSTR3 staining was present 
between TCs and ACs. Ten out of 14 (71%) lymph node involvements or distant metastases 
showed a staining pattern similar to that of their primary tumors (Table 4). The rest of the 
metastatic samples were considered negative even though the primary tumor showed 
immunoreactivity. 
SSTR4 
Overall, 11% (n=19) of the tumors showed moderate cytoplasmic reactivity for SSTR4, and 
6% (n=11) strong cytoplasmic reactivity (Fig 2b). Membranous reactivity was seen in 25 
tumors (14%) (Fig. 2a). There was no significant difference in the staining pattern between 
TCs and ACs. All metastatic samples showed staining patterns similar to those of the primary 
tumors (Table 4). 
SSTR5 
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SSTR5 staining was located on the cell membrane in 36% (n=62) of the tumors, while 32% 
(n=55) of them were considered positive based on the criteria presented in the methods 
section (Fig. 2a-b). No significant difference in the SSTR5 staining pattern was seen between 
TCs and ACs. Eleven metastatic samples (92%) presented a staining pattern similar to that of 
the primary tumors while one metastatic sample was considered positive even if the 
corresponding primary tumor showed no reactivity (Table 4). 
Co-expression patterns of somatostatin receptors 
All five SSTR stainings were available for 166 tumors. Of these, 160 (96%) were positive for 
at least one SSTR subtype, while six tumors were negative for all SSTRs (four TCs and two 
ACs). One TC tumor expressed all SSTRs.  
For correlation analysis between SSTR expressions, we used Spearman’s rank correlation 
and dichotomous classification positive/negative. According to this, SSTR1 expression was 
associated with SSTR2 and SSTR5, while SSTR4 appeared to be expressed when SSTR1, 2, 
and 5 were absent. Co-expression patterns are presented in Table 5. 
We also examined the distribution of other SSTR subtypes in tumors that were negative 
for SSTR2 (n=41). Among these, 7 tumors (17%) expressed SSTR1, 28 (68%) SSTR3, 19 
(46%) SSTR4, and 2 (5%) SSTR5. 
Somatostatin receptors and tumor size 
The mean tumor size was 1.9 cm (median 1.7 cm, range 0.5–5.5 cm). With Mann-Whitney U 
test we found a significant difference in tumor size between SSTR2 positive and negative 
tumors (P=0.011). SSTR2 positive tumors were on average 2.0 cm in diameter (median 2.0 
cm, range 0.5-5.5 cm) while SSTR2 negative tumors were smaller, on average 1.6 cm in 
diameter (median 1.5 cm, range 0.6-4.0 cm). Other SSTRs showed no association with tumor 
size (Table 6). 
Somatostatin receptors and tumor spread 
To evaluate the association between SSTR expression and tumor spread, we first assessed 
whether the expression of SSTRs was associated with lymph node involvement at the time of 
diagnosis (n=13). We observed that SSTR2 negative tumors (n=32) were more often 
accompanied by lymph node involvements compared with SSTR2 positive tumors (n=102) 
(7/32, 22% vs. 6/102, 6%, P=0.014). Also, tumors positive for SSTR4 behaved similarly 
(5/18, 28% vs. 8/115, 7%. P=0.017) (Table 6). 
To further examine the association of SSTR expression with tumor spread, we looked at 
the SSTR expression among patients who had metastatic disease at the time of diagnosis or 
who developed it during follow-up (n=19). We found again that SSTR2 negativity and 
SSTR4 positivity was associated with metastatic disease (9/45, 20% vs. 10/132, 8%, 
P=0.027; 7/28, 25% vs. 12/149, 8%, P=0.015, respectively). The same was seen for SSTR1 
negativity (14/81, 17% vs. 4/88, 5%, P=0.011) (Table 6).  
Treatment of metastatic disease is summarized in Table 2. Eleven patients received 
somatostatin analogs (lanreotide or octreotide) and/or peptide receptor radionuclide therapy 
(PRRT) with 177Lu-DOTATATE for metastatic disease. Clinical and/or radiological response 
to the treatment was observed in five patients (median progression free survival 52 months, 
range 32-114 months), and one patient did not respond. Somatostatin receptor profile of the 
primary tumor of the non-responding patient showed SSTR4 expression while responding 
patients did not have SSTR4 expression. 
Somatostatin receptors and patient outcome 
Patient follow-up ended on April 1, 2018. Of the 178 patients, 12 died with evidence of 
disease (five TC patients and seven AC patients) and 24 from unrelated causes. The survival 
time for patients with disease-specific death was on average 6.9 years (median 4.4 years, 
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range 1.1–17.4 years). Median time of observation for patients alive when follow-up ended 
was 11.6 years (average 13.1 years, range 4.6–28.0 years). 
To evaluate the association between SSTR expression and patient outcome, we first 
compared survival curves with the Kaplan–Meier method and the log-rank test in our overall 
cohort. We found that SSTR1 and SSTR2 negativity (P=0.009 and P=0.039, respectively) as 
well as SSTR3 (P=0.028) and SSTR4 positivity (P=0.047) was associated with shorter DSS 
(Fig. 3a-d). 
After this we assessed TC patients and AC patients separately. Within TC patients we did 
not find any association between SSTR status and survival. However, SSTR2 negativity 
(P=0.004) as well as SSTR3 and SSTR4 positivity (P=0.044 and P=0.004, respectively) were 
associated with disease-specific mortality among AC patients (Fig. 3e-g).  
Next, we performed univariate Cox survival regression analysis to investigate the effect 
of SSTR status on disease-specific survival (Table 7). In the whole patient series, SSTR3 
positivity was associated with increased risk of shorter survival, while SSTR1 expression was 
associated with improved outcome. When evaluating AC patients separately, SSTR2 
positivity was associated with better outcome and SSTR4 positivity with risk of shortened 
survival. Within TC patients we did not find any effect of SSTR status on DSS. Because of a 
low number of disease-specific deaths (n=12), we could not perform a reliable multivariate 
analysis. 
Discussion 
In the present study, we evaluated the SSTR subtype expression at protein level in a large set 
of patients with typical or atypical carcinoid tumors. A relatively high incidence of SSTR2 
(75%), SSTR3 (56%), and SSTR1 (52%) was observed, whereas SSTR5 (32%) and SSTR4 
(16%) were less commonly expressed.  
Previous studies (14-17, 23, 24) on SSTR expression in PC patients reported fluctuating 
expression levels: SSTR1 63–83%, SSTR2 43–96%, SSTR3 5–54%, SSTR4 0–14%, and 
SSTR5 0–71%. This may be due to applying different primary antibodies as well as scoring 
protocols over time. Some of the studies have also utilized the TMA technique, while others 
have used whole tissue sections. In addition, apart from the studies performed by Kanakis et 
al. (15) and Righi et al. (16), PC patient numbers have been limited in previous studies. Our 
study comprised 178 well-characterized patients with long follow-up time and survival data. 
In our series, SSTR2 was almost exclusively expressed on the cell membranes, while 
other receptors showed also a cytoplasmic staining pattern. A possible explanation for this is 
the SSTR internalization after ligand binding (25). To our knowledge, this is the first study to 
report a SSTR4 membranous staining pattern in pulmonary carcinoid tumors. All other 
studies found only cytoplasmic expression (14, 17) or no expression at all (15). In our series, 
25 tumors showed membranous expression. In addition to a large tumor number, this may be 
due to the novel, monoclonal antibody used, since other studies were performed with 
polyclonal antibodies.  
Both TCs and ACs expressed all SSTRs. The only difference in expression was observed 
for SSTR2: the expression of SSTR2 was more common in TCs than in ACs. Thus, the SSTR 
profile cannot be used for distinguishing between TC and AC. 
The SSTR expression in metastatic lesions (n=14) was mostly consistent with their 
primary tumors (concordance for SSTR1 83%, SSTR2 100%, SSTR3 71%, SSTR4 100%, 
and SSTR5 92%) which is in line with previous results (15). As histological metastatic 
samples are rarely available, a multi-center study to confirm this observation is needed. 
However, we suggest that the SSTR profile in metastasis could be used for treatment 
decision-making if tissue from the primary tumor is not available.  
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Currently the standard treatment of PC tumors is surgery, while there are no guidelines 
available for medical treatment of the metastatic disease (26). Nevertheless, in both the 
European Neuroendocrine Tumor Society (26, 27) and the North American Neuroendocrine 
Tumor Society (28, 29) consensus guidelines for diagnosing and treating PC patients, 
somatostatin analogs are mentioned as a treatment option. According to recent findings, SSAs 
are not only involved in the control of hormonal syndromes, but they also have a role as 
antiproliferative agents in neuroendocrine tumors (9, 30). Benefit of the SSA treatment with 
octreotide, lanreotide or 177Lu-DOTATATE for patients with metastatic pulmonary carcinoid 
tumor has been shown by multiple studies and was also confirmed in our study (31-35).  
The currently available SST analogs, octreotide and lanreotide, bind preferentially to 
SSTR2 and to a lesser extent to SSTR3 and 5, while pasireotide has an affinity especially for 
SSTR5 but also for SSTR1–3 (7, 9, 30). In our study, SSTR2, the major target of currently 
used SSAs, could not be interpreted as positive in 23% (n=41) of the tumors. However, 85% 
of these SSTR2 negative tumors expressed at least one of the other SSTRs, offering a 
rationale for treatment with analogs binding to receptors other than SSTR2. In particular, 
SSTR3 and 4 expressions were found in tumors negative for SSTR2, raising the thought that 
these patients might in the future benefit from somatoprim or KE108, which has a high 
affinity also for SSTR3 and SSTR4 (12, 36). Hence, a clinical trial for determining the level 
of immunohistochemical positivity needed for SSA treatment response should be carried out. 
As surgery represents the main treatment for PCs (26, 37), tissue material for 
immunohistochemical analysis of SSTRs is usually available. Different commercial 
monoclonal antibodies for SSTRs are currently available on the market, but they need to be 
thoroughly validated in clinical practice (38).  
When evaluating the association between SSTR status and tumor spread, we noticed that 
tumors negative for SSTR2 or positive for SSTR4 were more often accompanied by lymph 
node involvement at the time of surgery. SSTR4 positivity as well as lack of SSTR1 and 
SSTR2 expression was associated with distant metastasis. On the other hand, Kanakis et al. 
(15) studied SSTR expression in regard to lymph node involvement and distant metastasis but 
did not find any association. Righi et al. (16) reported that SSTR3 positivity correlated with 
lymph node metastasis. 
Kaemmerer et al. (14) showed that SSTR1 expression is a strong prognostic marker in 
bronchopulmonary neuroendocrine neoplasms. They noticed that patients with high SSTR1 
tumor expression had better outcome. However, they included also small cell lung cancer 
specimens in their analysis that are known to express less SSTR1 compared with PCs (17). 
They also described that hardly any TC or AC patient died. Nevertheless, we also noticed the 
same phenomenon: patients with SSTR1 positive tumor showed better outcome.  
Studies on gastroenteropancreatic neuroendocrine tumors have shown that expression of 
SSTR2 and SSTR5 is associated with improved survival (39-43). We did not find any 
association with survival when studying SSTR5, but SSTR2 expression was associated with 
longer DSS among all patients and among AC patients. Also, to the best of our knowledge, 
this is the first study to report that SSTR3 and SSTR4 expression is associated with shortened 
DSS in neuroendocrine tumors. 
The present study has some limitations. Firstly, since this was a retrospective study dating 
back to the 1990s, we do not have SSTR scintigraphy data to compare with 
immunohistochemical results. Secondly, we used TMAs instead of whole sections. However, 
as shown by Kanakis et al. (15), PC tumor cells lying in the periphery tend to express a 
stronger membranous staining pattern than those in the middle part of the tumor. For this 
reason, we chose to punch two 1 mm tissue cores from the tumor border as well as two from 
the middle of the tumor. We also utilized the next-generation TMA approach that has been 
shown to be highly accurate (44). 
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Our study can be considered representative since it comprises a large number of cases 
with up-to-date clinical follow-up and survival information. We also re-evaluated each tumor 
according to the latest WHO classification. Moreover, we used novel monoclonal antibodies 
for immunohistochemistry and optimized every staining protocol thoroughly in our 
laboratory.  
One drawback of our study is that our patient cohort included only a limited number of 
disease-specific deaths, despite a relatively long follow-up, resulting in the fact that reliable 
multi-variate analysis could not be performed. In addition, we experienced also a limited 
number of lymph node involvements (n=13), probably due to inappropriate surgical 
procedures concerning the tumors operated before year 2000. Nonetheless, given that PCs are 
rare tumors, this study remains one of the most comprehensive of its kind. 
In conclusion, our study strengthens the concept that information on SSTR expression at a 
tissue level might impact the treatment and follow-up protocol of PC tumor patients. We 
showed that PCs present a broad range of SSTRs, and that their expression is associated with 
tumor’s metastatic potential and patient outcome. Hence, SSTRs could be used as prognostic 
markers for PCs. Therefore, we recommend routine evaluation of the SSTR subtype status by 
immunohistochemistry for pulmonary carcinoid tumors. 
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Fig. 1. Evaluation of immunohistochemical staining for somatostatin receptors (SSTRs) 1–5. 
SSTR1 (a) showed both cytoplasmic and membranous staining while SSTR2 (b) was mainly 
membranous. SSTR3 (c) and SSTR4 (d) showed both cytoplasmic and membranous 
expression. SSTR5 expression was located on the cell membrane but was seen also in the 
cytoplasm (e). Images were taken with the CaseViewer software (3D HISTECH): whole 
TMA spot with magnification 10x, square image with magnification 40x. 
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Fig. 2. Expression of somatostatin receptors 1–5 in pulmonary carcinoid tumors. Frequency 
of any level membranous expression (a). Number of tumors considered positive based on 
both membranous and cytoplasmic staining (b). 
Fig. 3. Disease-specific survival probabilities for all pulmonary carcinoid patients based on 
somatostatin receptor (SSTR) 1 (a), SSTR2 (b), SSTR3 (c), and SSTR4 expression (d). 
Disease-specific survival probabilities for atypical carcinoid patients based on SSTR2 (e), 
SSTR3 (f), and SSTR4 (g) expressions. Blue lines are for negative staining and green ones 
for positive. P-values were calculated with the log-rank test. 
Table 1. Clinicopathological features and surgical procedures of the patients. 
Variable TC  AC  All  
Sex       
Male 46 (67%) 20 (50%) 66 (37%) 
Female 92 (33%) 20 (50%) 112 (63%) 
Age       
mean 53  55  53  
median 55  56  55  
range 19–84  23–77  19–84  
Surgical procedure       
Enucleation 3 (2%) 0 0 3 (2%) 
Lobectomy 67 (54%) 23 (61%) 90 (53%) 
Bilobectomy 9 (7%) 2 (5%) 11 (7%) 
Segmentectomy 15 (12%) 1 (3%) 16 (10%) 
Wedge resection 11 (9%) 1 (3%) 12 (8%) 
Sleeve resection 17 (14%) 8 (21%) 25 (17%) 
Pneumectomy 1 (1%) 3 (8%) 4 (3%) 
Unknown 15  2  17  
Tumor size (cm)       
≤1 38 (28%) 11 (28%) 49 (28%) 
1.1–2.9 78 (57%) 20 (49%) 97 (55%) 
≥3 11 (15%) 9 (23%) 30 (17%) 
Hilar/mediastinal (N1/N2) nodal involvement at 
diagnosis       
Yes 6 (6%) 7 (19%) 13 (10%) 
No 92 (94%) 29 (81%) 121 (90%) 
Not examined 40  4  44  
Distant metastasis       
At diagnosis 1 (1%) 1 (5%) 2 (1%) 
During follow-up 8 (6%) 9 (23%) 17 (10%) 
Ki-67 labeling index       
<1% 53 (39%) 11 (28%) 64 (37%) 
1–2% 68 (51%) 21 (52%) 89 (51%) 
>2% 13 (10%) 8 (20%) 21 (12%) 
TC, typical carcinoid tumor; AC, atypical carcinoid tumor 
Table 2. Treatment of metastatic disease and response to somatostatin analogs. Median time 
from primary surgery to metastatic disease was 26 months (average 46 months, range 7-239 
months). 
Variable Number of patients 
Treatment  
Metastases surgery only 3 
Chemo/radiotherapy only 4 
SSA only 2 
SSA+chemo/radiotherapy 5 
SSA+PRRT 1 
SSA+PRRT+chemo/radiotherapy 3 
No treatment, only follow-up 1 
Clinical/radiological response to SSA and/or PRRT  
response 5 
stable disease 2 
slow progression 1 
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no response 1 
not applicable due to concurrent chemotherapy 2 
SSA, somatostatin analog; PRRT, peptide receptor radionuclide therapy 
Table 3. Features of the somatostatin receptor (SSTR) antibodies and staining protocols used 
for immunohistochemistry. 
Antibody Supplier Clone Dilution Incubation (min) Pre-treatment Detection 
SSTR1 Abcam (ab137083) UMB7 1:500 45 Tris-EDTA pH 9.0 EnVision 
SSTR2a Abcam (ab134152) UMB1 1:300 32 CC1 std OptiView 
SSTR3 Abcam (ab137026) UMB5 1:7000 60 Citrate pH 6.0 EnVision 
SSTR4 Bio-Rad (MCA5922) sstr4 1:500 30 Citrate pH 6.0 EnVision 
SSTR5 Abcam (ab109495) UMB4 1:1000 30 Citrate pH 6.0 EnVision 
aThis antibody was called SSTR2A in some of the previous studies 
Table 4. Somatostatin receptor (SSTR) profile of primary tumor sample and corresponding 
metastatic sample. 
Primary tumors Metastatic  
samples 
 SSTR1 SSTR2 SSTR3 SSTR4 SSTR5 
 pos neg pos neg pos neg pos neg pos neg 
positive 3 0 6 0 7 4 8 0 2 0 
negative 2 7 0 8 0 3 0 6 1 9 
concordance 83% 100% 71% 100% 92% 
Table 5. Co-expression of somatostatin receptor (SSTR) 1–5 based on Spearman’s rank 
correlation coefficient. 
 SSTR1 SSTR2 SSTR3 SSTR4 SSTR5 
SSTR1  r=0.408 r= −0.275 r= −0.280 r=0.515 P=0.000 P=0.001 P=0.001 P=0.000 
SSTR2 r=0.408  r= −0.112 r= −0.457 r=0.345 P=0.000 P=0.170 P=0.000 P=0.000 
SSTR3 r= −0.275  r= −0.112  r=0.138 r= −0.324 P=0.001 P=0.170 P=0.092 P=0.001 
SSTR4 r= −0.280 r= −0.457 r=0.138  r= −0.232 P=0.001 P=0.000 P=0.092 P=0.008 
SSTR5 r=0.515 r=0.345 r= −0.324 r= −0.232  P=0.000 P=0.000 P=0.001 P=0.008 
Table 6. Analysis of somatostatin receptor (SSTR) association with clinicopathological 
factors. 
Factor SSTR1 SSTR2 SSTR3 SSTR4 SSTR5 
Tumor size no negative tumors 
smaller, P=0.011 no no no 
Lymph node 
involvement no 
negativity 
associated, P=0.014 no 
positivity 
associated, P=0.017 no 
Distant metastasis negativity 
associated, P=0.011 
negativity 
associated, P=0.027 no 
positivity 
associated, P=0.015 no 
Table 7. Analysis of somatostatin receptor (SSTR) expressions as potential risk factors for 
disease-specific death using univariate Cox survival regression model. 
Risk factor All patients Atypical carcinoid patients 
 HR 95% CI P value HR 95% CI P value 
SSTR1 pos vs. neg 0.167 0.037-0.765 0.021   0.119 
SSTR2 pos vs. neg   0.050 0.08 0.01-0.70 0.022 
SSTR3 pos vs. neg 4.703 1.027-21.533 0.046   0.080 
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SSTR4 pos vs. neg   0.060 6.64 1.48-29.64 0.013 
SSTR5 pos vs. neg   0.231   0.577 
HR, hazard ratio; CI, confidence interval 
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